National HMO Enrollment by State
HMO penetration analyses by state are affected by a number of factors, say industry experts. They include: employer offerings; employee incentives: the mix of commercial, Medicare and Medicaid enrollees; and national employers listing enrollment by home state rather than where enrollees live.
"With these limitations, my impression is that a potential cause of the small decline overall nationally, and in particular in the state with the largest enrollment, is the shifting of enrollees from HMOs into consumer-driven, high-deductible health plans," according to Joseph M. Mack, MPA, senior vice president at the National Healthcare Practice in the Irvine, Calif., office of Beecher Carlson, an Atlanta-based insurance brokerage and risk management firm. "These plans typically pay as a PPO rather than an HMO. Consequently, as employees shift from HMOs to consumer-driven plans, there is a decline in total HMO enrollment."
Pay for performance
"If this is true, then lower performing groups actually are spending more time and money to comply with pay for performance, only to receive a lesser portion of the incentive income because they were originally performing below the mean," he says. "Physicians have to ask themselves if it makes business sense to continue to participate in such programs if they have to invest capital . . . to comply and report pay-for-performance measures, or if there are other reimbursement programs . . . that will pay them more than they receive from HMOs, with little or no change to their existing practices."
-Tracey Walker
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 13th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
